Asia Beat: Dying to survive in South Korea
This article was originally published in Scrip
Observers could be forgiven for likening the recent move by South Korea's government to slash the prices of patent-expired drugs to a simmering bowl of bibimbap, a well-known dish in the national cuisine.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.